Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Summary not available.